Bevacizumab is under clinical development by Outlook Therapeutics and currently in Phase III for Branch Retinal Vein Occlusion. According to GlobalData, Phase III drugs for Branch Retinal Vein Occlusion have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Bevacizumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Bevacizumab overview
Bevacizumab (Lytenava) is a humanised monoclonal antibody produced in Chinese hamster ovary cells by recombinant DNA technology that acts as an anti-neo-vascularization agent. It is formulated as a solution for intravitreal route of administration. Lytenava is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (nAMD).
Bevacizumab-vikg is under development for the treatment of wet age related macular degeneration, diabetic macular edema, branch retinal vein occlusion and other retinal diseases. The drug candidate is a monoclonal antibody developed based on Biosymphony platform. It is administered through intravitreal route in the form of solution. It acts by targeting vascular endothelial growth factor A (VEGFA).
Outlook Therapeutics overview
Outlook Therapeutics is a biopharmaceutical company. It develops, manufactures and commercializes biosimilar products in the areas of ophthalmology. The company pipeline product includes ONS-5010 Lytenava, repackaged bevacizumab, ophthalmic anti-VEGF among others. The company is investigating its lead product candidate, ONS-5010 an ophthalmic formulation of bevacizumab-VIKG intended to treat wet age-related macular degeneration (AMD), diabetic macular edema (DME), branch retinal vein occlusion (BRVO) and other retinal diseases. It also collaborates with biotechnology and pharmaceutical companies to develop its products. Outlook Therapeutics is headquartered in Cranbury, New Jersey, the US.
For a complete picture of Bevacizumab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
